Impact of SGLT2 inhibitors on long-term outcomes in TAVI patients with heart failure: a propensity-matched analysis
Revista Española de Cardiología (English Edition) · 2026
DOI: 10.1016/j.rec.2025.10.016 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Revista Española de Cardiología (English Edition), 2026. Verfasst von Omar Obeidat und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Central Florida, Orlando, Florida, United States. Hauptthemen laut MEDLINE: Heart Failure, Transcatheter Aortic Valve Replacement, Sodium-Glucose Transporter 2 Inhibitors, Aortic Valve Stenosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
INTRODUCTION AND OBJECTIVES: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes in heart failure (HF), but their role in patients undergoing transcatheter aortic valve implantation (TAVI) remains unclear. A recent randomized trial (DapaTAVI) showed reduced HF hospitalizations with SGLT2i post-TAVI, but effects on mortality and broader outcomes are unknown. METHODS: Using the TriNetX Research Network, we conducted a multicenter retrospective cohort study of adults with HF who underwent TAVI between 2015 and 2025. Patients prescribed SGLT2i within 30 days of TAVI were 1:1 propensity score-matched to nonusers. The primary outcome was all-cause mortality; secondary outcomes included hospitalizations, myocardial infarction, stroke, arrhythmias, and renal events. RESULTS: Among 58 193 TAVI recipients, 3022 SGLT2i users were matched to 3022 nonusers. SGLT2i use was associated with significantly lower mortality at 3 months (3.5% vs 4.9%; HR, 0.71), 6 months (5.0% vs 8.1%; HR, 0.61), 12 months (7.3% vs 10.5%; HR, 0.71), and 5 years (10.7% vs 20.6%; HR, 0.59; all P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Central Florida, Orlando, Florida, United States.
- Department of Medicine, Hamilton Medical Center, Dalton, Georgia, United States.
- Department of Medicine, Allegheny Health Network, Pensilvania, United States.
- Department of Cardiology, Southern Illinois University, Springfield, Illinois, United States.
- Division of Cardiovascular Medicine, William Beaumont University Hospital, Royal Oak, Michigan, United States.
- Cardiovascular Division, University of Minnesota, Minnesota, Minneapolis, United States.
Zitieren
APA
Obeidat, O., Alayyat, A., Naser, A., Ghanem, F., Jabri, A., Brankovic, M., Jiao, T., Ruzieh, M., Haddad, A., Alexy, T., Villablanca, P., & Alhuneafat, L. (2026). Impact of SGLT2 inhibitors on long-term outcomes in TAVI patients with heart failure: a propensity-matched analysis. Revista Española de Cardiología (English Edition). https://doi.org/10.1016/j.rec.2025.10.016
Vancouver
Obeidat O, Alayyat A, Naser A, Ghanem F, Jabri A, Brankovic M, et al. Impact of SGLT2 inhibitors on long-term outcomes in TAVI patients with heart failure: a propensity-matched analysis. Revista Española de Cardiología (English Edition). 2026. doi:10.1016/j.rec.2025.10.016
BibTeX
@article{Obeidat2026,
author = {Obeidat, Omar and Alayyat, Ahmad and Naser, Abdallah and Ghanem, Fares and Jabri, Ahmad and Brankovic, Milos and Jiao, Tianze and Ruzieh, Mohammed and Haddad, Alaq and Alexy, Tamas and Villablanca, Pedro and Alhuneafat, Laith},
title = {Impact of SGLT2 inhibitors on long-term outcomes in TAVI patients with heart failure: a propensity-matched analysis},
journal = {Revista Española de Cardiología (English Edition)},
year = {2026},
doi = {10.1016/j.rec.2025.10.016}
}
EUVIMED